In 1999, Lilly became one of the first pharmaceutical companies to establish a standing bioethics committee to systematically identify, evaluate, and communicate bioethics issues. In 2008, we took our first steps toward a more dedicated approach to bioethics and established the Lilly Bioethics Program, devoting full-time resources to the area. The program is an independent organizational unit within Lilly with dedicated senior leadership by the vice president of global patient safety and bioethics. Full-time staff with graduate training in bioethics is responsible for the program’s development, oversight, and deliverables. The program also includes part-time effort in the form of the Lilly bioethics advisory committee (BEAC) and the Lilly bioethics network (BEN).
The Lilly Bioethics Program is designed to address the increasingly complex ethical challenges of global pharmaceutical research and development (R&D) in today’s fast-paced biotechnology environment. The program is a global framework that governs the full sweep of Lilly’s R&D activities. It promotes ethical research and drug development, safeguards the integrity of the scientific process, protects patients’ well-being, and ensures that animals are treated humanely. The program’s purpose is to assist employees in identifying and addressing bioethical issues related to Lilly’s R&D activities.
The Lilly Bioethics Program has developed bioethics positions on relevant and emerging topics, including stem cell research, human biological samples, and the choice of control for clinical trials.
To learn more, visit the Lilly Bioethics page.
The Lilly Bioethics Program is designed to address the increasingly complex ethical challenges of global pharmaceutical Research & Development (R&D) in today's fast-paced biotechnology environment.